Multi-billion dollar fine on Pakistan puts the spotlight on a secret court

Source: ISDS Bilateral

3rd September 2019

JPEG - 106.7 kb

TRT | 21 August 2019

Multi-billion dollar fine on Pakistan puts the spotlight on a secret court

by Saad Hasan

The Reko Diq mine case shows the overreach of a secretive arbitration system.

Last month, the International Centre for Settlement of Investment Disputes (ICSID), a global quasi-court, slapped more than a $5 billion fine on Pakistan in an arbitration case involving a gold and copper mine.

But the ICSID, which is part of the World Bank Group, didn’t initially announce its decision. There was nothing on its website. Except for perhaps the lawyers involved in the case, hardly anyone had seen the judgement*.

Continue reading

Advertisements
Posted in ISDS | Leave a comment

The Drug Pricing Conundrum: Why Transparency Reforms Are Necessary to Make Healthcare Accessible

Source: News 18

26th August, 2019

 

While an intellectual property system that includes safeguards for early introduction of generics does reap price-lowering benefits for India, making transparency reforms part of its agenda will spotlight the mark-ups, production costs and the actual R&D investments by companies vis-à-vis that is underwritten by tax subsidies.

Leena MenghaneyJyotsna Singh

Updated:August 16, 2019, 8:59 AM IST

The Drug Pricing Conundrum: Why Transparency Reforms Are Necessary to Make Healthcare Accessible

The spiralling costs of monopoly medicines is a universal problem that is not only confined to India. Although governments agree that medicines should be made more affordable, they are reluctant to initiate and implement policies against the abusive patenting, pricing and business practices of pharmaceutical corporations due to their immense lobbying influence.

Therefore reforms to make medicines more affordable are thus, glacially slow. Transparency reforms, however, may just change the status quo.

Continue reading

Posted in Drug prices, Transparency | Leave a comment

FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access

Source: Health Policy Watch

21st August 2019

 

The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease.

Pretomanid is only the third TB drug to be approved in over 50 years, and amidst the excitement from achieving this milestone, activists are calling for the developer and newly licensed producer of pretomanid to ensure that those most in need of the treatment will be able to access it.

Continue reading

Posted in Access to Medicins, Tuberculosis (TB) | Leave a comment

FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis

Source: Health Policy Watch

19th August, 2019

 

NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) as part of a three-drug, six-month, all-oral regimen for the treatment of people with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive (collectively “highly drug-resistant TB”).1,2

Continue reading

Posted in Tuberculosis (TB) | Leave a comment

Letter to PM on Info Service on Health Issues

Source: Third World Network

13th August, 2019

 

TWN Info Service on Health Issues (May19/03)
9 May 2019
Third World Network

Shri J. P. Nadda
Hon’ble Minister of Health and Family Welfare
Room No. 348, ‘A’ Wing
Nirman Bhavan, New Delhi-110011

29th April, 2019

Dear Nadda ji,

Ad-hoc donations of bedaquiline threaten sustainable, affordable access for patients; Create conflict of interest for MOHFW in regulating Johnson & Johnson

As treatment activists, public health organizations, patients affected by TB and patients affected by Johnson & Johnson’s (J&J) faulty hip implants, we are writing in response to the recent announcement about a second round of donations of 10,000 courses of bedaquiline (BDQ) by J&J to the IndianGovernment [1].

Continue reading

Posted in Access to Medicins, Tuberculosis (TB) | Leave a comment

Indian civil society pushes for ‘Government Use’ compulsory license on MDR-TB Drugs

Source: Lawyers collective

13th August, 2019

 

Survivors of drug resistant tuberculosis, health organisations and the TB community in India and across the globe have appealed to the Prime Minister of India to issue a government use compulsory license for two of the essential drugs for Drug-Resistant Tuberculosis (DR-TB) treatment- Bedaquiline and Delamanid to encourage generic competition.

 

Continue reading

Posted in Tuberculosis (TB) | Leave a comment

Civil Society letter to minimize injectables and scale up new drugs in drug-resistant tuberculosis (DR-TB) regimen

13th Aug, 2019

 

To,
Dr. K.S. Sachdeva, Addl DDG, Central TB Division, MoHFW, NirmanBhawan, New Delhi – 110011
Mr. Sanjeeva Kumar, Additional Secy (Health), MoHFW, 254-A, NirmanBhawan, New Delhi – 110011
Prof. Vinod K. Paul, Member, NITI Aayog, Government of India, 115, NITI Aayog, Sansdmarg, New Delhi – 110001

Dr. Raman R. Gangakhedkar, Scientist, ICMR, Ansari Nagar, New Delhi – 110029

Date: 21/12/18

Submission: Minimize injectables and scale up new drugs in drug-resistant tuberculosis (DR-TB)regimens

Dear Dr. Sachdeva , Mr. Kumar, Prof. Paul and Dr. Gangakhedkar,

We are representing people affected by DR-TB, various health organizations and people living with HIV. With 1.47 lakh citizens affected every year and mortality rates that are amongst the worst in the world, DR-TB continues to pose a major public health challenge in the country. Given this back ground we raise some genuine concerns on access to Bedaquiline (Bdq) and Delamanid (Dlm) and in addition adequate Drug Sensitivity Testing (DST) facilities throughout the country.

Continue reading

Posted in Tuberculosis (TB) | Leave a comment